Application of T Cell lmmunotherapy for Human Viral and Malignant Diseases
Improvements in our understanding of the molecular basis for T cell recognition of virus-infected cells and tumors, and of the signals involved in eliciting and maintaining a competent immune response has led to new efforts to bolster host T cell immunity in settings where deficient responses permit disease progression. The identification of viral antigens and antigens expressed by tumors has led to efforts to develop adoptive immunotherapy with T cell clones as a therapeutic approach to restore or augment host responses (Riddell and Greenberg 1995). The early results of clinical studies of T cell therapy for viral diseases have been encouraging and this approach is now being developed for the treatment of patients with leukemia that recurs after allogeneic bone marrow transplant (BMT) and patients with solid tumors.
KeywordsGraft Versus Host Disease Major Histocompatibility Complex Molecule Adoptive Immunotherapy Bone Marrow Transplant Recipient Immediate Early
Unable to display preview. Download preview PDF.
- Boeckh MRS, Cunningham T, Myerson D, Flowers M, Bowden R (1996) Increased risk of late CMV infection and disease in allogeneic marrow transplant recipients after ganciclovir prophylaxis is due to a lack of CMV-specific T cell responses. Blood (suppl): 1195AGoogle Scholar
- Bonnet D, Warren EH, Greenberg PD, Dick J, Riddell SR (1999) CD8+ minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate AML skin cells. Proc Natl Acad Sci USA 3: 730–737Google Scholar
- Bueger M de, Bakker A, Van Rood JJ, Van der Woude F, Goulmy E (1992) Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol 149: 1788–1794Google Scholar
- Els CA van, D’Amaro J, Pool J, Blokland E, Bakker A, Elsen PJ van, et al (1992) Immunogenetics of human minor histocompatibility antigens: their polymorphism and immunodominance. Immunogenetics 35: 161–165Google Scholar
- Evans LS, Witte PR, Feldhaus AL, et al (1999) Expression of a GM-CSF/IL-2 chimeric receptor in human CTL clones results in GM-CSF dependent growth. Hum Gene Ther 10: 1942–1951Google Scholar
- Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, et al (1988) Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 108: 806–814Google Scholar
- Klein MR, Baalen CA van, Holwerda AM, Kerkhof Garde SR, Bende RJ, Keet IP, et al (1995) Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 181: 1365–1372PubMedCrossRefGoogle Scholar
- Quinnan GV Jr, Kirmani N, Rook AH, Manischewitz JF, Jackson L, Moreschi G, et al (1982) Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med 307: 7–13Google Scholar
- Wills MR, Carmichael AJ, Mynard K, Jin X, Weekes MP, Plachter B, et al. (1996) The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 70: 7569–7579PubMedGoogle Scholar